// 1

INSPIRING THE WORLD

TO MOVE WELL

INVESTOR UPDATE

JULY 2017

For

per

sona

l use

onl

y

// 2

This presentation does not constitute investment, legal, taxation or other advice and the

presentation does not take into account your investment objectives, financial situation or particular

needs. You are responsible for forming your own opinions and conclusions on such matters and

should make your own independent assessment of the information presented. No responsibility is

accepted by dorsaVi or any of its respective officers, employees, agents, advisers or associates

for any of the information or for any action taken by you on the basis of that information. Any and

all use of the information is at your own risk.

Certain information may relate to protected intellectual property rights owned by dorsaVi Ltd (the

"Company”). Except as required by law, no representation or warranty, express or implied, is

made as to the accuracy, completeness or correctness of the information, opinions and

conclusions, or as to the reasonableness of any assumption contained in this presentation. By

receiving this information and to the extent permitted by law, you release dorsaVi and its

respective officers, employees, agents, advisers and associates from any liability (including,

without limitation, indirect or consequential loss or damage, or loss or damage arising by

negligence) arising as a result of the reliance by you or any other person on anything contained in

or omitted from this document or presentation.

DISCLAIMERF

or p

erso

nal u

se o

nly

// 3

• Investment highlights

• About dorsaVi

• Operational update

• ViSafe overview

• ViMove overview

• ViPerform overview

• Outlook

AGENDA

INSPIRING THE WORLD TO MOVE WELL™

REVOLUTIONARY

WEARABLE SENSOR

TECHNOLOGY

For

per

sona

l use

onl

y

// 4INVESTMENT HIGHLIGHTS

• First mover advantage, leader with medical grade wearable technology – FDA, CE Mark, TGA approved

• Three attractive markets – Occupational Health & Safety, Clinical, and Elite Sports

• Across three geographic markets – US, UK and Australia

• FY 17 revenue up 15% on FY16 FY (21% in constant currency)

• US FY17 161% up on US FY16 revenue ($450k to $1.18K AUD)

• US reimbursement supporting US roll out

• Annuity revenue building in the US clinical and OHS market

• Large operational leverage:

• Costs stable

• US agency model (7 agents in Americas)

• Annuity revenues emerging from the OHS market through myViSafe product:

• Successful launch in Australia, UK and US markets

• Mini sensors and App used in the OHS market that create annuity revenue

• Launch of smaller and easier to use mini sensors ViMove2:

• Driving more rapid and online sales growth in Australian market

• FDA clearance for ViMove2 for US launch Q3/Q4 2018

• Lower COGS, attractive margins and payback

For

per

sona

l use

onl

y

// 5

About dorsaVi

For

per

sona

l use

onl

y

// 6BOARD AND SENIOR MANAGEMENT

Non Executive Director

Michael Panaccio

Chairman

Herb Elliott

Non Executive Director

Greg Tweedly

Non Executive Director

Ash Attia

Director & CEO

Andrew Ronchi

CFO

Damian Connellan CIO

Meagan Blackburn

CPO

Muhammad Umer

CMO

Megan Connell Head of Sales and

Operations Europe

Zoë Whyatt

Head of Sales and

Operations Australia

Matt May

Head of Sales and

Operations US

Mark Heaysman

For

per

sona

l use

onl

y

// 7OUR BUSINESS: SOLID FOUNDATION FOR GROWTH

• Three key business divisions with diversified revenue streams

• Occupational health and safety

• Clinical

• Elite sports

• Market leader with first mover advantage

• Patent protected technology

• Significant barriers to entry and limited competition

• FDA approval

• TGA approval

• CE Mark

• Currently focused on three key geographies

• United States

• United Kingdom

• AustraliaFor

per

sona

l use

onl

y

// 8STRONG PRODUCT PORTFOLIO

• Patent protected movement algorithms

on medical-grade sensor technology

• Function-specific applications which

deliver meaningful movement data to

our target markets

• OHS solution to determine, measure and mitigate high risk activities

• Significant appetite for innovative manual handling solutions

• Executive and board-level focus on reducing injuries and

associated costs

• Budget readily available

• Growing portfolio of products to capitalise on opportunities

• Clinical solution with turnkey applications for low back, running and

a range of other functional measures

• Early adopter advocates in key geographic markets of

Australia, US and UK

• Distribution partners in US and UK

• Elite sporting solution used in off-field

environments to measure stress and prevent injury

• Widespread use across many codes – AFL,

NRL, NBA, NFL, NHL, EPL

• Sporting business growing via word of

mouth

For

per

sona

l use

onl

y

// 9

?

For

per

sona

l use

onl

y

// 10

Operational Update

For

per

sona

l use

onl

y

// 11

FINANCIAL OVERVIEW

dorsaVi Ltd (ASX : DVL)

Share price $0.35

Shares on issue 167,305,859

Market capitalisation $58.6M

2013 2014 2015 2016 2017

Revenue 398,607 529,380 1,358,218 3,019,928 3,466,000*

EBITDA (2,148,749) (3,852,593) (8,684,709) (5,915,567) N/A

Loss from

continuing

operations

(1,659,235) (3,562,024) (8,036,161) (5,237,102) N/A

Cash position $13.94M $5.74M $6.03M $8.61M

*unaudited results

For

per

sona

l use

onl

y

// 12

GROWTH IN MAJOR MARKETS

UKAU US

For

per

sona

l use

onl

y

// 13

EXECUTION ACROSS THE PRODUCT LINES

ViSafe (OHS)• ViSafe continues to grow across all three geographic markets

• Launched myViSafe - self managed solution within ViSafe portfolio creating annuity revenue

• Scalable across small to large corporations

ViMove (Clinical)• Launch of ViMove2 – App-based mini sensors, new price point, reduced COGS

• US: Select Medical (2,000 clinical sites) Initial pilot 20 (currently at 40 sites)

• Clinical trial shows ViMove reduces pain by 45% & improves function by 73%

• Health economic paper released which shows ViMove delivers both improved clinical

outcomes and reduced economic impact

ViPerform (Sport)• NBA Teams (LA Lakers), NFL Teams (New England Patriots)

• NHL (Philadelphia Flyers)

• Initial US College sites (Ohio State & Marquette)

• Athletic Movement Index most popular module in USA

For

per

sona

l use

onl

y

// 14

REDUCING COSTS & INJURY

IMPROVING PRODUCTIVITY

BUILDING SAFETY CULTURE

For

per

sona

l use

onl

y

// 15F

or p

erso

nal u

se o

nly

// 16

SCALABLE REVENUE MODEL

ASSESS SOLVE IMPLEMENT

AUDIT +

MONITOR +

TRAIN +

COMPARE +

SOLVE PROBLEMS =

TRANSFORM +

EMBED +

COMMUNICATE +

DELIVER +

AFFECT CHANGE =

SCOPE +

COLLECT +

COMPARE +

UNDERSTAND =

$40,000 $100,000 $300,000

For

per

sona

l use

onl

y

// 17

myViSafe BUSINESS MODEL

• Self managed solution for organisations to

monitor employee movement

• Key applications

• Manual handling training

• Compliance testing

• Issue identification

• Accessible to a very large market – for

organisations with more than 100 employees

• High volume solution, low touch support

• Attractive price point – starting at $9,500

• Software licence $10k - $70K p.a.

• Scalable annuity revenue from small to large

corporates

http://dmdatabases.com/databases/business-mailing-lists/how-many-businesses

No. of Employees No. of Businesses

5,000+ 3,518

1,000 – 4,999 11,338

100 - 999 214,948

Number of US businesses appropriate for myViSafe

For

per

sona

l use

onl

y

// 18

AGENT MODEL BUILDING FOR RAPID REVENUE GROWTH

Scalable model:

• Direct sales representatives in key

markets

• Sales partnerships with agents

• 7 agents signed up across US

• Centralised analysis

For

per

sona

l use

onl

y

// 19

FDA CLEARED, CE MARK, TGA

SUPPORTED BY CLINICAL

TRIAL DATA

For

per

sona

l use

onl

y

// 20

THE INVESTMENT CASE FOR ViMove2

Benefits of ViMove2 for dorsaVi and Investors

• $5M development over 2 years with market feedback from 3 geographies

• Significantly reduced COGS allowing scalable model

• Faster, easier to use product to drive utilisation

• Reduces training and face to face time from 4 hours to 10 minutes

• Product designed to enhance patient experience

• Allows easier entry into new geographies

• Business model $3k up front and $3k p.a.

Geo No. of Physios

Australia 24,000

UK 48,000

USA 284,000

Number of Physiotherapists

For

per

sona

l use

onl

y

// 21

LOW BACK KNEERUN

For

per

sona

l use

onl

y

// 22

ViMove2 RUN

ViMove2 Run enables clinicians to

quickly understand how a runner is

moving – gait lab in your own clinic.

Tests

• Distance

• Speed

• Style

What is measured

• Leg Symmetry

• Average Ground Reaction Force

• Average Initial Peak Acceleration

• Average Ground Contact Time

• Average Steps Per Minute

• Total Distance

• Average Speed

• Time

• Access reports

• View assessment data

• Follow prescribed

exercise programs

For

per

sona

l use

onl

y

// 23

ViMove2 LOW BACK

ViMove2 Low Back quickly gains a clearer picture by assessing

lumbar spine movement in real-time, automatically prescribing

exercises that are appropriate for patients based on the

assessment data.

Tests

• Lumbar Lordosis

• Flexion

• Extension

• Lateral Flexion

• Standing Pelvic Tilt

• Sitting Posture

• Sitting Pelvic Tilt

• Sitting Rotation

What is measured

• Range of Movement

• Postural Angles

• Quality of Movement

For

per

sona

l use

onl

y

// 24

ViMove2 KNEE

Historically it has been difficult to visualise quality of knee movement, especially

in dynamic movements such as hopping and landing. With ViMove2 Knee,

clinicians can quickly assess the stresses and strains placed on a patient’s

knees in real-time.

Tests

• Double Leg Squat

• Single Leg Squat

• Hop

What is measured

• Tibial Inclination

• Valgus and Varus Range of Movement

• Valgus and Varus Speed

• Flight Time

For

per

sona

l use

onl

y

// 25

AUSTRALIAN CLINICAL MARKET

24,000 Physios in Australia

• Conservative cottage industry

• Not commercial minded

• Critical thinkers

• Very hands on model (1:1)

• Lean business model (low margins)

• Tech averse

• 4 years to sign on >100 sites

• 80% retention rate

For

per

sona

l use

onl

y

// 26

284,000 Physical Therapists in the USA

• Franchise model with acquisitions occurring

• Commercially minded

• Less hands on

• Treat multiple patients at a time (1:4)

• More tech savvy

• Outreach business model

• Schools and colleges screening large numbers

• 2 years to sign on 160 sites

• 100% retention rate

CLINICAL SCALE IN THE US MARKETdorsaVi clinical sites and number of PT’s by state

Bureau of Labour Statistics, OES May 2016 Data (https://www.bls.gov/oes/tables.htm)

For

per

sona

l use

onl

y

// 27

CLINICAL TRIAL SHOWS TREATMENT AND COST BENEFIT

• 8 week program

• 45% pain

• 73% function

• Lasting benefit at 12 months

• Exceptional health economic

outcomes

RANDOMISED

CONTROLLED TRIAL

Peer reviewed clinical trial showing dramatic improvement

for low back pain

“This evaluation has identified that motion-sensor

biofeedback intervention using ViMove system

was both more effective and less costly overall

than the control from the societal perspective.

Rarely are health care interventions found to

be both more effective and less costly overall”

Professor Terry Haines (Monash University)

Clinical Treatment Benefit Economic/Cost Benefit

For

per

sona

l use

onl

y

// 28

BRANDING AND

CREDIBILITY

For

per

sona

l use

onl

y

// 29

ELITE SPORTS MARKET: WORKING WITH INNOVATORS

• Working with thought leaders

• Growth through word of mouth

For

per

sona

l use

onl

y

// 30

APPLICATIONS IN THE RETAIL & CONSUMER WORLD

• Retail groups need point of differentiation to attract shoppers

• Runners stores, pharmacies, consumer retailers

• Engaging tech and immediate feedback works

• Strong evidence for increase in sales from use of customers own data

For

per

sona

l use

onl

y

// 31

OutlookF

or p

erso

nal u

se o

nly

// 32

WORLD LEADERS USING dorsaVi TECHNOLOGY

MEDICAL DEVICES

• Large companies with a special interest in movement

• Track and monitor patient both pre & post surgery

• Want to provide better outcomes for their product

PHARMACEUTICALS

• Independent evidence on how their drugs are performing

• Are people moving better?

• Do the patients have less muscle spasm?

HOSPITALS

• Aiming to reduce admissions

• Monitor patients at home and engage them in recovery

• Conduct commercial pilots using cutting edge tech

• Publish trial results with KOLs as authors

UNIVERSITIES

• Develop better treatment protocols

• Conduct sophisticated clinical trials using new

tech outcomes

• Educate the next generation of clinicians and ergonomists

For

per

sona

l use

onl

y

// 33

UPCOMING NEWSFLOW

• Annuity revenue growing with myViSafe in major geos

• Traction of ViMove2 in the Australian clinical market

• New OHS contracts with major corporates (US, UK & Australia)

• Continue to grow US OHS sales agents

• Custom applications with market leaders

For

per

sona

l use

onl

y

// 34

dorsaVi™

Andrew Ronchi

PhD (Eng), B.App.Sci (Physio)

Chief Executive Officer

Level 1, 120 Jolimont Road,

East Melbourne, Victoria 3002

Office: +61 9652 2192 | Mobile: +61 417 882 267

ar@dorsaVi.com | dorsaVi.com

For

per

sona

l use

onl

y